Veeva price target raised to $201 from $195 at Morgan Stanley

Morgan Stanley analyst Craig Hettenbach raised the firm’s price target on Veeva (VEEV) to $201 from $195 and keeps an Underweight rating on the shares. Veeva beat in Q4 and provided “mixed” guidance for FY26, says the analyst, who adds that operating margin was “a clear bright spot” despite lingering crosscurrents across the Life Sciences vertical. However, there is still a major platform migration to manage through and “work to be done to drive an acceleration in growth implied” by 2030 targets, the analyst tells investors.